Cargando…
Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor
We have examined the effects of intravenous infusion of recombinant human tumour necrosis factor (rh-TNF) on serum activity of phospholipase A(2) (PLA(2)) in patients with malignancies. Nine patients received a 24 h continuous intravenous infusion ranging from 1.0 × 10(5) U/m(2) to 3.0 × 10(5) U/m(2...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365345/ https://www.ncbi.nlm.nih.gov/pubmed/18475466 http://dx.doi.org/10.1155/S0962935192000358 |
_version_ | 1782154145622392832 |
---|---|
author | Pruzanski, Waldemar Sherman, Matthew L. Kufe, Donald W. Vadas, Peter |
author_facet | Pruzanski, Waldemar Sherman, Matthew L. Kufe, Donald W. Vadas, Peter |
author_sort | Pruzanski, Waldemar |
collection | PubMed |
description | We have examined the effects of intravenous infusion of recombinant human tumour necrosis factor (rh-TNF) on serum activity of phospholipase A(2) (PLA(2)) in patients with malignancies. Nine patients received a 24 h continuous intravenous infusion ranging from 1.0 × 10(5) U/m(2) to 3.0 × 10(5) U/m(2); 14 patients received a 5 day continuous intravenous infusion ranging from 0.5 × 10(5) U/m(2)/day to 3.0 10(5) U/m(2)/day. Twenty one of 23 patients responded with marked increases in serum PLA(2) activity that were detectable 3 h after the beginning of the rh-TNF infusion and reached maximum levels at 18 h with a mean increase of 16.2-fold. In patients receiving a 5 day rh-TNF infusion, the highest levels of PLA(2) were observed after the first day of infusion. Serum PLA(2) activity declined continuously to 2.9-fold above baseline at the end of the infusion. A significant correlation was noted between the dose of infused rh-TNF and the maximum increase in PLA(2) activity. To our knowledge, this is the first time that an association between intravenous TNF administration and induction of circulating PLA(2) in man has been established. |
format | Text |
id | pubmed-2365345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-23653452008-05-12 Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor Pruzanski, Waldemar Sherman, Matthew L. Kufe, Donald W. Vadas, Peter Mediators Inflamm Research Article We have examined the effects of intravenous infusion of recombinant human tumour necrosis factor (rh-TNF) on serum activity of phospholipase A(2) (PLA(2)) in patients with malignancies. Nine patients received a 24 h continuous intravenous infusion ranging from 1.0 × 10(5) U/m(2) to 3.0 × 10(5) U/m(2); 14 patients received a 5 day continuous intravenous infusion ranging from 0.5 × 10(5) U/m(2)/day to 3.0 10(5) U/m(2)/day. Twenty one of 23 patients responded with marked increases in serum PLA(2) activity that were detectable 3 h after the beginning of the rh-TNF infusion and reached maximum levels at 18 h with a mean increase of 16.2-fold. In patients receiving a 5 day rh-TNF infusion, the highest levels of PLA(2) were observed after the first day of infusion. Serum PLA(2) activity declined continuously to 2.9-fold above baseline at the end of the infusion. A significant correlation was noted between the dose of infused rh-TNF and the maximum increase in PLA(2) activity. To our knowledge, this is the first time that an association between intravenous TNF administration and induction of circulating PLA(2) in man has been established. Hindawi Publishing Corporation 1992 /pmc/articles/PMC2365345/ /pubmed/18475466 http://dx.doi.org/10.1155/S0962935192000358 Text en Copyright © 1992 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Pruzanski, Waldemar Sherman, Matthew L. Kufe, Donald W. Vadas, Peter Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title | Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title_full | Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title_fullStr | Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title_full_unstemmed | Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title_short | Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor |
title_sort | induction of circulating phospholipase a(2) by intravenous administration of recombinant human tumour necrosis factor |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365345/ https://www.ncbi.nlm.nih.gov/pubmed/18475466 http://dx.doi.org/10.1155/S0962935192000358 |
work_keys_str_mv | AT pruzanskiwaldemar inductionofcirculatingphospholipasea2byintravenousadministrationofrecombinanthumantumournecrosisfactor AT shermanmatthewl inductionofcirculatingphospholipasea2byintravenousadministrationofrecombinanthumantumournecrosisfactor AT kufedonaldw inductionofcirculatingphospholipasea2byintravenousadministrationofrecombinanthumantumournecrosisfactor AT vadaspeter inductionofcirculatingphospholipasea2byintravenousadministrationofrecombinanthumantumournecrosisfactor |